Treating metastatic prostate cancer in very elderly men: a review

A helpful review article on the treatment of metastatic and metastatic, castration-resistant prostate cancer (mCRPC) in very elderly men appears in last month’s issue of Clinical Interventions in Aging. … READ MORE …

Results of Prostvac PROSPECT trial scheduled for later in 2017

According to Barvarian Nordic, the key results of the Phase III clinical trial of the immunologic agent Prostvac (rilimogene galvacirepvec/rilimogene glafolivec, or “rilimogene”) in treatment of metastatic, castration-resistant prostate cancer (mCRPC) are now expected in the second half of 2017. … READ MORE …

No sign of evident clinical benefit in the Phase IV PLATO trial

According to a recent media release, there was no significant benefit for the investigational combination of enzalutamide (Xtandi) + abiraterone acetate (Zytiga) + prednisone in treatment of men with chemotherapy-naive, metastatic, castration-resistant prostate cancer (cnmCRPC). … READ MORE …

Data from the Phase III clinical trial of ipilimumab

Just over 3 years ago, Bristol-Myers Squibb announced that treatment with ipilimumab (Yervoy) had failed to show a survival benefit in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). For readers who may be interested, the data from this trial have finally been reported by Beer et al. in the Journal of Clinical Oncology.

Non-rising PSA but radiographic progression in men on treatment with enzalutamide

A recent presentation at the European Society of Medical Oncology (ESMO) annual meeting in Copenhagen, Denmark, has suggested that some men on treatment with enzalutamide (Xtandi) may have radiographic progression of their cancer even though there is no increase in their PSA levels. … READ MORE …

Combination therapy with radium-223 and abiraterone acetate in mCRPC

We understand from the manufacturers that the so-called ERA-223 trial — a randomized, double-blind, multi-center, Phase III trial of radium-223 acetate (Xofigo) + abiraterone acetate (Zytiga) + prednisone compared to a placebo + abiraterone acetate + prednisone — is now fully enrolled. … READ MORE …

Abiraterone acetate + dutasteride in treatment of mCRPC

Does adding dutasteride (Avodart) to abiraterone acetate (Zytiga) make any difference in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC)? There is no clear answer to this question from a small, Phase II, pilot study, the results of which have just been published in Clinical Cancer Research. … READ MORE …